Exploring Zwitterionic Coronas as Alternatives to Traditional PEG Architectures for Improved siRNA Polyplex Pharmacokinetics and Tumor Delivery by Jackson, Meredith Allyn
 Exploring Zwitterionic Coronas as Alternatives to Traditional PEG Architectures for Improved 
siRNA Polyplex Pharmacokinetics and Tumor Delivery 
 
By 
 
Meredith A. Jackson 
 
Thesis 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements  
for the degree of 
 
Master of Science 
in 
 
Biomedical Engineering 
December, 2016 
Nashville, Tennessee 
 
Approved: 
Craig L. Duvall, Ph.D. 
Todd D. Giorgio, Ph.D. 
 
 
 
  
 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2016 by Meredith A. Jackson 
All Rights Reserved 
  
iii 
 
ACKNOWLEDGMENTS 
 
 I would like to thank my advisors, Dr. Craig Duvall and Dr. Todd Giorgio, for supporting 
me throughout this work. Thanks to Dr. Duvall for conceiving the original idea behind the 
project, for giving me scientific guidance throughout, and for encouraging me to persevere 
through the many interesting challenges it posed. I would also like to thank several key members 
of both the Duvall and Giorgio labs whose assistance was invaluable to this project. Thank you 
to Thomas Werfel for providing me with my initial training in the lab, for answering countless 
questions, and for weighing in on difficult problems. Thank you to my undergraduate colleagues, 
Ayisha Jackson, Zoe Johnson, and Elizabeth Curvino, for their assistance at various stages. 
Thank you to Kameron Kilchrist for assistance with intravital microscopy and to Samantha 
Sarett for assistance with flow cytometry. Thank you to Taylor Kavanaugh and Dr. Fang Yu for 
assistance with animal care and tail vein injections. Thank you to Mary Dockery and Stephanie 
Dudzinski for assistance with in vivo tumor uptake studies. Thank you to Dr. Mukesh Gupta and 
Dr. Eric Dailing for providing general chemistry-related guidance. Finally, I would like to extend 
a general thanks to all members of the Duvall, Giorgio, and Sung labs for creating such a 
supportive and positive environment in which to work. 
I would also like to thank Dr. Don Stec for NMR training and assistance at various points 
in this project. Dynamic Light Scattering was performed using instrumentation in the Vanderbilt 
Institute of NanoScale Sciences and Engineering (VINSE), and Isothermal Titration Calorimetry 
measurements were performed using the Vanderbilt Center for Structural Biology core facilities. 
This work was supported by the Vanderbilt School of Engineering, the Department of Defense 
through DOD PRORP OR 130302, and by the National Science Foundation Graduate Research 
Fellowship under Grant No. 1445197.  
iv 
 
TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS ......................................................................................................................... iii 
LIST OF TABLES ........................................................................................................................................ v 
LIST OF FIGURES ..................................................................................................................................... vi 
Chapter 
I. Background .............................................................................................................................................. 1 
 siRNA Therapeutics ................................................................................................................................. 1 
 Nanocarrier Delivery for Cancer Therapeutics ........................................................................................ 2 
  
II.  Introduction .............................................................................................................................................. 4 
 
III.  Results and Discussion ......................................................................................................................... 6 
 
 Synthesis of Diblock Copolymers with Varied Corona Chemistries ....................................................... 7 
 Synthesis and Stability Characterization of siRNA Polyplexes ............................................................... 9 
 In vitro Characterization ........................................................................................................................ 13 
 Protein Adsorption ................................................................................................................................. 14 
 In Vivo Pharmacokinetics....................................................................................................................... 17 
 In Vivo Tumor Gene Silencing and Biodistribution ............................................................................... 21 
 
IV.  Conclusion .......................................................................................................................................... 28 
 
V. Materials and Methods ........................................................................................................................... 29 
 
 
 REFERENCES .......................................................................................................................................... 40 
 
APPENDIX ................................................................................................................................................. 47 
  
A. Supplemental Figures ...................................................................................................................... 50 
 
 
 
  
  
 
 
 
 
v 
 
LIST OF TABLES 
 
Table                                                                                                                                           Page  
1. Polymer Synthesis Results ........................................................................................................................ 8 
2. Polyplex Size, Zeta Potential, and Polydispersity ................................................................................... 10 
3. Pharmacokinetic Parameters ................................................................................................................... 19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
LIST OF FIGURES 
 
Figure                                                                                                                                         Page  
1. Six Polyplexes with Different Surface Chemistries .................................................................................. 8 
2. Polyplex siRNA Encapsulation Efficiency and Overall Stability ............................................................. 9 
3. Polyplex Stability in Increasing Salt Concentrations .............................................................................. 11 
4. Polyplex Stability over Time .................................................................................................................. 12 
5. In Vitro Polyplex Characterization ......................................................................................................... 14 
6. Polyplex-Protein Interactions .................................................................................................................. 16 
7. In Vivo Pharmacokinetics and Biodistribution ........................................................................................ 18 
8. Panel of Intravital Microscopy Images ................................................................................................... 20 
9. In Vivo Tumor Bioactivity ...................................................................................................................... 23 
10. Polyplex Tumor Biodistribution ........................................................................................................... 25 
10. In Vivo Tumor Uptake of Polyplexes .................................................................................................... 26 
11. Supplement: NMR of All Polymers ...................................................................................................... 46 
12. Supplement: Raw Average Radiance Data  .......................................................................................... 49 
 
 
 
 
  
 1 
 
CHAPTER I 
 
BACKGROUND 
siRNA Therapeutics 
The field of siRNA-based therapeutics has come a long way since the first discovery of 
these short, 19-30 base oligonucleotides with potent mRNA silencing abilities in C. elegans in 
1998.1  These siRNA molecules are active in the cytoplasm, where they bind to complementary 
mRNA at the RNA-induced Silencing Complex (RISC), and activate degradation of the mRNA 
transcript.2 Because of their high specificity for target mRNA, siRNAs hold great potential for 
treatment of a variety of disease states while also minimizing off target side effects common with 
traditional, non-specific small molecule drugs. In the nearly 20 years since the discovery of 
siRNA, over 50 clinical trials with siRNA-based therapeutics have occurred 3. The siRNAs used 
in these trials were designed to have IC 50 values in the nanomolar to picomolar range, making 
them extremely potent gene silencers3.  
 While early clinical trials focused on local delivery of siRNAs for treatment of such 
ocular diseases as age-related macular degeneration, diabetic macular edema, and glaucoma, 
later trials have delivered siRNA systemically for treatment of liver-related diseases or cancers.3, 
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 In each of these trials, siRNAs were encapsulated in nanoparticle-based systems. These 
carrier systems are often necessary because siRNAs are large, hydrophilic macromolecules with 
poor pharmacokinetics in their free form.3 Upon intravenous injection, free siRNAs are rapidly 
degraded by nucleases in serum. Backbone modifications such as 2’-O-methyl modifications can 
prevent such fast nuclease degradation.6 However, because of their size, siRNAs are also prone 
to glomerular filtration and therefore fast excretion via the kidneys.7 Even if free siRNAs were to 
overcome these barriers, their negative charge results in extremely low tissue permeability, 
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making it difficult to impossible for free siRNA to pass through cell membranes and reach their 
targets. Additionally, any siRNAs taken up by cells would be trapped in endosomes and 
degraded in lysosomes, never reaching the RISC target in the cytoplasm.2 
Nanoparticulate carriers pose a solution to the problem of poor systemic bioavailability of 
free siRNA. Nanoparticles can protect siRNAs from nuclease degradation, reduce glomerular 
filtration (due to their large size), and increase transport across cell membranes depending on 
their physicochemical properties.3 In the field of nucleic acid delivery, traditional encapsulation 
methods can be divided into two main categories—viral delivery and non-viral delivery. 8 In the 
arena of non-viral particulate systems, the most common carrier systems are either lipid-based or 
polymer-based.9 Typically, in these systems, the negative charge of siRNA is leveraged via 
complexation with a cationic lipid or cationic polymer, resulting in effective encapsulation 
within a carrier. Both polymer and lipid-based siRNA vectors have been studied in clinical trials 
and shown to effectively deliver siRNA to therapeutic site of action with promising mRNA 
knockdown results.3  While both types of systems have their respective advantages and 
disadvantages, polymer-based systems may be less immunogenic than lipid-based systems, as  
the CALAA-01 clinical trial involving cyclodextrin-based delivery systems, had lower 
immunogenicity as compared to other clinical trials involving lipid-based systems.10 Most lipid-
based systems have been developed to target the liver preferentially to treat hepatic diseases, but 
such targeting is not necessarily optimal for treatment of cancer, where delivery to solid tumors 
is preferred.11-14  
Nanocarrier Delivery for Cancer Therapeutics 
 Because of the strong role genetic mutations play in the development and progression of 
cancer, siRNA holds great potential for cancer therapeutics. It is believed that siRNA gene 
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silencing depends on the rate of cell division, however, posing a challenge in the arena of cancer 
therapies.10, 15 For liver disease, because hepatocytes are relatively quiescent, silencing is more 
durable and only monthly treatment administration is necessary15. Cancer, on the other hand, is 
characterized by rapid division of cells, resulting in potential dilution of siRNA silencing 
effects.15 Thus, the need for repeat administration of therapeutic siRNAs necessitates invention 
of optimal nanocarriers that are safe and reliable delivery vehicles.  
 Nanoparticle-based drug delivery vehicles are frequently used to target solid tumors 
passively via a phenomenon known as the enhanced permeation and retention effect (EPR). This 
phenomenon, first described by Maeda and colleagues in 1986, states that because of the fast rate 
of cancer growth and progression, blood vessels surrounding tumor tissue are often ill-formed, 
tortuous, and as a result, more permeable than normal vasculature, with larger pore sizes.16 
Nanoparticles with sizes around 50-200 nm can easily fit through vascular pores in tumor tissue, 
but not through vascular pores in normal tissue, making them selective for tumor tissue. 17, 18This 
provides a great advantage for nanotechnology, because it theoretically reduces the likelihood of 
experiencing negative side effects based on cell death in normal tissues. In recent years, the EPR 
effect has been called in to question. Several researchers have argued that in humans, the EPR 
effect is extremely variable and unreliable, making it difficult to judge which patients might 
benefit from nanoparticle-based drug therapies.19 However, results from early phase siRNA 
carrier clinical trials have indicated target mRNA knockdown and siRNA delivery to tumor 
tissues, providing great hope for the future of nanoparticle-based therapeutics in cancer as the 
nuances of the EPR effect continue to be explored and leveraged appropriately.3, 10  
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CHAPTER II 
INTRODUCTION 
 Since their discovery in 1998, small interfering RNAs (siRNAs) have shown great 
promise as human therapeutics for a variety of diseases, including cancer, with many clinical 
trials completed or currently in progress.1, 3, 10 However, because of the poor pharmacokinetic 
properties of free siRNA, there remains a major need for optimized nanoparticle carriers to 
improve their systemic bioavailability and delivery to solid tumors.6, 9 Many cationic polymer 
systems have been developed to fill this need, but delivery challenges remain. Because of the 
relatively small fraction of cardiac output a tumor receives in the context of the entire body, a 
nanocarrier must remain in systemic circulation for extended periods in order to passively 
accumulate at the site of a tumor via the enhanced permeation and retention effect (EPR) enough 
to have a significant therapeutic effect at the target site.20, 21 
Upon intravenous administration, an siRNA- polymer complex (polyplex), encounters a 
complex in vivo environment that can result in carrier destabilization or clearance by phagocytic 
cells as primary elimination mechanisms. 20, 22, 23 Polyplexes can disassemble in circulation when 
they encounter anionic heparin sulfates at the kidney glomerular basement membrane, or any 
number of serum proteins that might penetrate polymer layers and compete with electrostatic 
interactions between polymer and siRNAs.23-25 Similarly, protein adsorption can also make 
nanocarriers more recognizable to macrophages of the mononuclear phagocyte system (MPS), 
resulting in phagocytosis or potential activation of the complement system if complement 
proteins adsorb.22, 26-28 Nanocarrier surfaces, as the primary point of exposure to the in vivo 
environment, play a key role in how protein coronas form and therefore how particle 
biodistribution occurs.29 As a result of these properties, as well as size and charge, it is a well-
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known fact that most nanoparticulate systems ultimately end up in the liver and spleen, organs of 
the reticuloendothelial system (RES).  
 The most common and exhaustively explored method for increasing particle stability, 
reducing protein adsorption, and improving pharmacokinetics is the use of PEGylation. The 
importance of PEG molecular weight, architecture, and surface density for increasing particle 
circulation time has been widely studied.30-39 However, equally well-documented is the fact that 
proteins can still penetrate PEG layers, resulting in opsonization, destabilization, rapid 
phagocytosis, and RES accumulation in spite of the added steric stabilization.25, 30, 40, 41 
Additionally, many studies have shown that PEG can be immunogenic and decrease overall cell 
uptake, including tumor cells.40, 42 IgG and IgM have been shown to bind to PEG, enhancing 
complement activation.40 PEG is also prone to the Accelerate Blood Clearance phenomenon 
(ABC), in which repeat injections of PEGylated carriers result in faster RES clearance due to 
immunogenic effects. 43-45 
 An exciting alternative to PEGylation that is under-studied in the field of siRNA delivery 
is zwitteration of polyplex coronas. Zwitterionic surfaces are extremely hydrophilic and interact 
electrostatically with water as compared to PEG, which hydrogen bonds with water.46-48 One 
type of zwitterion, in particular, phosphorylcholine, has found widespread use for anti-fouling 
applications and is an FDA-approved component of contact lenses and drug-eluting stents.46, 49-51 
Phosphorylcholine-based polymers are hemocompatible, easy to synthesize, and can mimic non-
thrombogenic surfaces of red blood cells, which contain many phosphorylcholine groups. The 
use of zwitterions in various nanocarriers has improved in vitro stability, cell uptake, and in 
some, cases, in vivo pharmacokinetics.52-57 While MPC has been incorporated into a few siRNA 
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or pDNA delivery vehicles for both in vitro and in vivo applications, it has never been directly 
compared to PEG architectures for in vivo pharmacokinetics or siRNA delivery to tumors.56, 58-61  
 Our previous work has focused on optimization of the core-forming block of polymers 
containing a balanced ratio of cationic and hydrophobic monomers (Dimethylamino ethyl 
methacrylate (DMAEMA) and Butyl Methacrylate (BMA)), respectively), for improved blood 
stability, bioactivity, and pH-responsive, endosomolytic properties of siRNA carriers.62 These 
previously-optimized carriers have utilized a 5kDa linear PEG as their corona-forming block to 
improve polyplex stability.  
In the present study, we have preserved the optimal core-forming components of our 
siRNA polyplexes but synthesized novel corona blocks in order to compare PEG to zwitterionic 
methacryloyloxy ethyl phosphorylcholine (MPC)-based polymers in terms of in vivo 
pharmacokinetics, as well as in vivo tumor accumulation and gene knockdown. In other work, 
we and others have sought to improve PEGylated nanocarrier pharmacokinetics through the use 
of a brush PEGylation architecture or high molecular weight Y-shaped PEGs, to varying degrees 
of success.33, 34, 63, 64 Therefore, we also compare MPC coronas to these alternative PEG 
architectures in addition to our traditional linear polymer architecture.   
To our knowledge, this is the first study to compare MPC-based siRNA polyplexes to 
traditional PEGylated siRNA polyplexes in terms of in vivo pharmacokinetics and anti-tumor 
activity. Additionally, we are the first to use intravital confocal microscopy to thoroughly 
characterize the impact of surface chemistry on in vivo pharmacokinetics of nanocarriers.  
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CHAPTER III 
RESULTS AND DISCUSSION 
Synthesis of Diblock Copolymers with Varied Corona Chemistries 
In total, six diblock copolymers were synthesized with a pH-responsive core block 
composed of a random copolymer with an equimolar ratio of dimethylaminoethyl methacrylate 
(DMAEMA) and butyl methacrylate (BMA). The corona blocks consisted of a 5kDa linear PEG, 
a 20kDa linear Y-shaped PEG, a 10kDa zwitterionic MPC-based corona, a 20kDa zwitterionic 
MPC-based corona, a 10kDa poly(ethylene glycol) methyl ether methacrylate (POEGMA) block, 
or a 20kDa POEGMA (Figure 1).  
 The 5k linear PEG, 10k MPC, and 10k POEGMA corona lengths were chosen because 
they were the shortest corona lengths that would form micellar structures using these materials. 
The 20k MPC and 20k POEGMA were chosen as standards to compare to the 20kDa Y-shaped 
PEG, which has previously shown superior pharmacokinetics to shorter PEG coronas33.  
For the linear PEG-containing polymers, the core block was RAFT polymerized from a 
linear PEG5k or linear Y-shaped PEG 20k macroCTA. For the MPC or POEGMA-containing 
polymers, the core block was RAFT polymerized first, followed by a second, facile RAFT 
polymerization of a corona-forming block of appropriate length. Due to the advantages of RAFT 
polymerization, all polymers had low polydispersity and were easily synthesized at the desired 
block lengths (Table 1).  
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Figure 1. Six polyplexes with different surface chemistries. All polyplexes contain the 
same core block consisting of DMAEMA and BMA, with different corona blocks as pictured. 
Polymer structures are displayed on the left, with core block in red and corona block in blue.  
 
 
Table 1: Polymer Synthesis Results. All polyplexes were synthesized at the desired 
corona block lengths with 50:50 molar ratios of DMAEMA:BMA. Polydispersity indices were 
low. * MPC polymers were not analyzed with GPC due to insolubility in mobile DMF phase. 
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 Synthesis and Stability Characterization of siRNA Polyplexes 
 To form polyplex micelles, polymer and siRNA were mixed at various N:P ratios at low 
pH, allowed to complex 30 min, and then the pH was raised to 7.4 to allow for spontaneous 
micellization. The results of a Ribogreen assay evaluating the encapsulation efficiency of these 
polyplexes shows that for all of the polyplexes except 20k POEGMA DB, siRNA was almost 
completely encapsulated at an N:P ratio of 5, but the highest encapsulation efficiencies (~80%) 
were achieved at N:P of 20 (Figure 2A). Additionally, we found that all of the polyplexes had 
higher stability at N:P 20 than N:P 10 after a 5 min incubation with heparin sulfate salts (Figure 
2B). Thus, the remaining studies were carried out using an N:P ratio of 20.  
 
 
Figure 2: Polyplex siRNA encapsulation efficiency and overall stability is highest at N:P 20. A) 
Ribogreen assay reveals ~80% encapsulation efficiency at N:P 20. B) Average stability of all 
polyplexes at N:P 10 vs N:P 20 in 30% FBS or 80 U/mL Heparin. P<0.01. 
 
 Importantly, despite their varied corona molecular weights and characteristics, all 
polyplexes had sizes close to 100 nm and near-neutral zeta potentials. Thus, although size and 
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surface charge are known to highly affect pharmacokinetics28, these factors did not vary 
significantly between each polyplex (Table 2).  
 
Table 2: Polyplex Size, Zeta Potential, and Polydispersity. All polyplexes were of uniform size 
and near neutral zeta potentials.   
 
Polyplex size and stability were further evaluated by introducing various salt 
concentrations into polyplex buffer. Figure 3 shows that the 20k MPC DB and 20k PEG DB 
polyplexes appeared most resistant to increasing salt concentrations based on dynamic light 
scattering traces, while the 5k PEG DB and POEGMA corona polyplexes were much less stable, 
losing their uniform size distribution and de-complexing at 0.25 M NaCl. This result indicated 
that larger coronas seemed to improve stability, but in the case of POEGMA-based polyplexes, 
increasing corona size did not improve stability.  
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Figure 3: Polyplex Stability in Increasing Salt Concentrations. Dynamic Light Scattering of 
polyplexes after introduction of 0, 0.1, or 0.25 M NaCl reveals superior stability properties of 
20k MPC DB and 20k PEG DB.  
 
In order to maximize polyplex accumulation at the site of the tumor, it is vital to design 
polyplexes that resist destabilization for as long as possible in the bloodstream.21 Two of the 
main sources of polyplex instability in intravenous circulation include serum proteins and 
anionic heparan sulfates in the kidney glomerular basement membrane.22-24 We hypothesized that 
our novel polyplex corona chemistries might improve polyplex stability in response to these 
challenges. We therefore co-encapsulated DNA containing Alexa Fluor -488 or Alexa Fluor-546 
fluorophores in the polyplex core and measured their FRET (forster resonance energy transfer) 
signal while simultaneously incubating polyplexes with varied amounts of either FBS or heparin 
sulfate (Figure 4A and 4B). Higher FRET signal indicated polyplex stability while decreased 
FRET signal indicated that the polyplexes had partially fallen apart in solution. In 10% serum, all 
polyplexes remained equally stable over time. However, at higher FBS concentrations, it 
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becomes clear that the novel polyplex coronas are better than linear 5k PEG at resisting 
destabilization. In the presence of heparin sulfate, the 20k Y-shaped PEG was clearly the most 
stable polyplex, but it was closely followed by the zwitterated polyplexes and the shorter 
POEGMA corona polyplex. Both the short 5k PEG and the 20k POEGMA polyplexes were least 
resistant to the heparin sulfate challenge. Thus, the most of the novel coronas provided the 
siRNA polyplexes with enhanced stability over the 5k PEG corona polyplexes. In the case of the 
20k POEGMA DB, which appears less stable than the other high molecular weight coronas, it is 
likely that the bulky side chains may be too large for enhanced polyplex stability.  
 
Figure 4: Polyplex Stability over Time. A) Polyplexes incubated in 50% (top), 30% (middle), or 
10% (bottom) FBS over 100 minutes show that most novel coronas improved FBS stability over 
5k PEG DB. B) In 80 U/mL, 40 U/mL, and 10 U/mL heparin salts, 20k PEG DB maintained 
greatest stability levels.  
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In vitro Characterization 
 Prior to our in vivo comparison of zwitterionic and PEGylated coronas, each polyplex 
was first evaluated for key in vitro properties to confirm their bioactivity and pH-responsiveness. 
Based on a red blood cell hemolysis assay described previously65, each of the polyplexes showed 
endosomolytic activity at pH values at or below 6.8, corresponding to pH’s found in the 
endolysosomal pathway, but no hemolytic properties at the physiological pH of 7.4 (Figure 5A). 
Because the pH-responsive behavior of these polyplexes is controlled by their core blocks, it is 
unsurprising that the different coronas did not differentially impact endosomolytic behavior.  
All polyplexes were evaluated for cytotoxicity using luciferase expressing NIH 3T3 
fibroblasts (Figure 5B). At 48 hours post-treatment, all cells maintained 87% or greater viability, 
indicating that none of the polyplex coronas increased cytotoxicity of these formulations.  
We also evaluated knockdown of the model gene luciferase in MDA-MB 231 cells by 
delivering siRNA against luciferase in each type of polyplex (Figure 5C). At 48 hours post 
treatment, cells exposed to 5k PEG, 20k PEG, or either zwitterated corona all retained less than 
10% luciferase activity (90% knockdown). For the POEGMA-based coronas, knockdown levels 
were less dramatic. 10k POEGMA achieved only around 50% knockdown, while 20k 
POEGMA-based polyplexes did not show any significant knockdown levels. This result suggests 
that the POEGMA-based coronas reduced in vitro bioactivity of polyplexes 
 Percent uptake of polyplexes by MDA-MB 231 breast cancer cells was also evaluated in 
vitro (Figure 5D). For the zwitterated coronas, 20k PEG, and 10k POEGMA coronas, 100% of 
cells were positive for polyplexes. For 5k PEG DB, this number was slightly lower (a significant 
decrease), and it was even lower for 20k POEGMA DB. Because this data correlates well with 
previous stability data, it suggests that the stability properties of the different coronas played a 
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more important role in cell uptake at 24 hours than the steric properties of the coronas 
themselves.  
 
Figure 5: In vitro Polyplex Characterization. A) All polyplexes retained similar pH-
responsiveness at pH ranges tested in hemolysis assay B) Polyplexes did not damage cell 
viability of NIH 3T3 fibroblasts at 100 nM siRNA. C) Luciferase knockdown in MDA-MB231 
cells was significantly improved for linear PEG and zwitterionic coronas, p<0.01. D) All novel 
polyplex coronas improved cell uptake over 5k PEG except 20k POEGMA, p<0.01.   
 
Protein Adsorption 
 Both PEGylation and zwitteration are designed to reduce protein adsorption to 
nanocarriers, because proteins mediate several nanocarrier clearance mechanisms. In general, 
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protein adsorption can make nanocarriers more identifiable to macrophages of the MPS or 
destabilize polyplexes, as discussed above. Similarly, if the proteins adsorbed are complement 
proteins like C3b, they can initiate a complement cascade further recruiting immune cells and 
promoting rapid clearance.26 We used two methods to evaluate how PEGylation and zwitteration 
might differentially affect protein adsorption---isothermal titration calorimetry and a hemolysis-
based complement assay.  
 Isothermal titration calorimetry (ITC) is an extremely sensitive method of assessing the 
thermodynamics of interaction between a protein and ligand.66, 67 In ITC, a protein solution is 
slowly titrated into a solution of polyplexes, and changes in heat resulting from their interaction 
are recorded. These heat changes can be extrapolated to measure entropy, enthalpy, and Gibb’s 
free energy of interaction between the protein and polyplexes. ITC has been used in the past to 
characterize protein adsorption to many different types of nanocarriers.66, 67 It is especially 
valuable for polyplex evaluation because siRNA polyplexes do not sediment, and therefore they 
cannot be evaluated by most traditional protein adsorption assays. Albumin was here used as a 
model for serum proteins, since it makes up the largest component of human serum. Overall, 
each polyplex, whether PEGylated or zwitterated, had a positive Gibb’s free energy of 
interaction with albumin (Figure 6A). This indicates that albumin binding was not spontaneous 
and therefore unfavored. However, the magnitude of (delta G) values were higher for the higher 
molecular weight coronas as compared to their lower molecular weight counterparts, indicating 
albumin adsorption was least favorable for these coronas. The 20k linear Y-shaped PEG corona 
had the largest dG values of any polyplex and was significantly higher than any other polyplex. 
It was followed by the 20k MPC polyplex, indicating that the 20k PEG corona was slightly more 
protein resistant than the 20k MPC corona. All polyplexes were compared to a positive control 
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polyplex containing cationic DMAEMA in its corona. This cationic control showed extremely 
negative dG values indicating a highly favorable interaction with albumin.  
 In order to evaluate potential complement activation by the various corona chemistries, 
we used a hemolytic assay modified from Bartlett and colleagues.66 Polyplexes were incubated 
with various dilutions of human complement sera and then antibody-sensitized sheep 
erythrocytes were added to each mixture. If complement proteins do not adsorb to polyplex 
coronas, then they are free to lyse the erythrocytes. However, if complement adsorption does 
occur, red blood cell lysis is reduced as fewer proteins are available to cause lysis. For all 
polyplexes, we did not observe significant differences in lysis compared to the complement only 
protein controls, meaning that complement adsorption was negligible (Figure 6B). The cationic 
DMAEMA corona control polymer, on the other hand, showed extremely reduced lysis 
compared to the complement only control, indicating significant adsorption, as expected. The 
20k POEGMA corona polyplex exhibited slightly increased lysis levels compared to the protein 
only control, probably as a result of its greater instability in serum. Thus, overall, the novel 
coronas do not display significant levels of complement activation.  
 
Figure 6: Polyplex-Protein Interactions. A) Isothermal Titration Calorimetry of polyplexes 
indicated significantly less favorable BSA interaction for 20k PEG DB than for other polyplexes, 
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p<0.01. B) Negligible complement protein adsorption was observed for all polyplex surface 
chemistries.  
   
In Vivo Pharmacokinetics 
 While several in vitro methods can assist in predicting in vivo stability, the best way to 
identify potential differences between zwitterated and PEGylated polyplex coronas is through in 
vivo pharmacokinetic studies. Traditional methods of characterizing nanocarrier 
pharmacokinetics have relied on multiple blood draws and extrapolation to determine initial 
nanocarrier blood concentrations. Intravital confocal laser scanning microscopy, on the other 
hand provides real time second-by-second tracking of fluorescence in the mouse ear blood 
vessels, while using fewer animals.68, 69 It provides a more thorough quantification of particle 
pharmacokinetics and is therefore a more accurate way to discern differences between 
PEGylated and zwitterionic coronas. For this study, polyplexes were loaded with Cy5-
conjugated DNA and the fluorescence signal tracked for 20 minutes.  
 Intravital microscopy revealed superior pharmacokinetic properties for 20k PEG DB and 
20k MPC DB polyplexes (Figure 7A-D). Qualitative differences from representative ear images 
can be visualized in Figure 8. Pharmacokinetic half-lives for each of these polyplexes were 
around 22 minutes (20k PEG DB) and 26 minutes (20k MPC DB), while half-lives for all other 
polyplexes ranged from 5-8 minutes (Table 3). Area under the curve for these polyplexes, when 
extrapolated to infinity, was very significantly highest for 20k MPC DB and 20k PEG DB, 
though there were no significant differences between these two coronas. Similarly, these two 
polyplexes also exhibited the slowest clearance values. Based on the intravenous 
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pharmacokinetic signal from these polyplexes, it appears that only the higher molecular weight 
zwitterionic and linear PEG coronas retained their stability for an extended period.  
 
Figure 7: In vivo pharmacokinetics and biodistribution. A) Average fluorescence intensity 
curves from mouse ear recorded for 20 minutes of imaging (n=4). B) Area under curve from t=0 
min to t=20 min. C) Area under curve from t=0 min to t= infinitity. 20k PEG DB and 20k MPC 
DB had significantly improved area under the curves compared to other polyplexes. D) Organ 
biodistribution at 20 minutes for all polyplexes.  
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Table 3: Pharmacokinetic Parameters. Quantification of pharmacokinetic parameters based 
on analysis from Graphpad Prism. 20k PEG DB and 20k MPC DB had superior 
pharmacokinetic properties to other polyplexes.  
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Figure 8: Panel of intravital microscopy images. Intravital microscopy allows for visualization 
of pharmacokinetic differences between polyplexes.  
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 Organ biodistribution data further supported this result (Figure 7D). Overall, there was 
minimal polyplex accumulation in the heart and lungs. All of the novel coronas had slightly 
decreased accumulation in the liver as compared to traditional linear PEG, which had the lowest 
average half-life. 20k POEGMA DB, the least stable of the polyplexes, had the highest 
accumulation in the kidneys, most likely a result of its poor resistance to heparin sulfate. There 
were no significant differences in the distribution profile between 20k PEG DB and 20k MPC 
DB. However, the fluorescence from the 20k MPC DB polyplexes is more shifted toward the 
liver than the kidneys as compared to the 20k PEG DB polyplexes. While the goal of these 
stealth coronas is to avoid RES uptake, this result may indicate that more of the 20k MPC DB 
polyplexes stay intact in the blood stream for longer (polyplexes that have fallen apart and 
released the Cy5 DNA would have more signal in the kidneys due to glomerular filtration). Thus, 
this result may be promising because if circulation and liver accumulation are increased, this 
increases the likelihood that tumor accumulation will also increase via the EPR effect. While the 
% of total fluorescence for the PEG DB appears higher in the liver, overall fluorescence at 20 
min was lowest for PEG DB in all organs (Supplemental Figure S2), implying that large 
amounts of these polyplexes had already been eliminated.  
 
In Vivo Tumor Gene Silencing and Biodistribution 
 It was hypothesized that because of the superior pharmacokinetics of 20k PEG DB and 
20k MPC DB, these two polyplex carriers should exhibit improved tumor accumulation and 
therefore improved gene silencing compared to 5k linear PEG DB carriers. We therefore 
established luciferase expressing MDA-MB 231 tumors in nude mice and intravenously injected 
20k PEG DB, 20k MPC DB, or 5k PEG DB bearing luciferase or scrambled siRNAs. The 
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animals received a single dose at 1 mg/kg siRNA once tumors had grown to roughly 75 mm^3, 
and were imaged after luciferin injections on Day 1, 3, 5, 7, and 10 post-injection (Figure 9A). 
The relative luminescence of each individual tumor was compared to its luminescence prior to 
polyplex injection, and these values were normalized to the average relative luminescence values 
for the scrambled control polyplexes. There were no significant differences in relative 
luminescence between any scrambled control polyplex groups, indicating no major tumor 
toxicity from the carriers alone.  
Throughout the 10 day period post-injection, mice treated with 20k MPC DB polyplexes 
containing luciferase siRNA exhibited potent and robust gene silencing (Figure 9B). Throughout 
the treatment, relative luminescence values for 20k MPC DB averaged about 20% that of 
scrambled controls. Both 20k PEG DB and 5k PEG DB exhibited lower relative luminescence 
values compared to their scrambled controls, but the % luminescence of 20k PEG DB was not 
significantly different from that of PEG DB throughout the study timeline. This study suggests 
that despite their similar pharmacokinetic properties, 20k MPC DB has superior in vivo 
bioactivity compared to 20k PEG DB.  
A few polyplex-related deaths were observed in the tumor-bearing mice that were not 
previously observed in the pharmacokinetic studies with CD-1 mice. Five mice, all from 
different polymer treatment groups, died within an hour after polyplex injection. There were no 
statistically significant differences in survival between polyplex groups (Figure 9D). We 
hypothesize that the high polymer concentration needed for a polyplex N:P ratio of 20 at 1 mg/kg 
siRNA led to dose-related toxicities. As a result of toxicity concerns, mice body weights were 
recorded each day during the study period, and there were no significant weight changes or 
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differences between polyplex treatment groups (Figure 9C). Future work is needed to optimize 
polyplex dose ranges.  
 
Figure 9: In vivo tumor bioactivity A) Mice treated once and imaged according to pictured 
schedule. B) 20k MPC DB had superior in vivo luciferase knockdown properties compared to 5k 
PEG DB and 20k PEG DB on Days 3-7 (n=6-10 tumors per group), p<0.05. C) Mouse body 
weight measurements indicated no major toxicity from single treatment. D) Overall survival was 
not significantly different between treatment groups.  
 
In order to elucidate the mechanism behind the superior tumor gene knockdown of 20k 
MPC DB, tumor-bearing mice were injected with polyplexes containing Cy5 DNA and 
sacrificed at either 2 hours or 24 hours. At each of these time points, organs were imaged for 
fluorescence using in vivo imaging system, and tumors were processed for flow cytometry. 
Corroborating our previous pharmacokinetic data, organ biodistribution results indicated that at 2 
hours, 5k PEG DB was higher in the kidneys, but mostly cleared from circulation by 24 hours. 
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20k MPC DB and 20k PEGDB fluorescence were much higher than 5k PEG DB in the kidneys 
at 24 hours, implying a longer blood residence time and slower clearance mechanisms (Figure 
10 A-D). Interestingly, there were no statistically significant differences in tumor fluorescence 
between the lead polyplexes at either time point.  
Closer analysis of tumor uptake data from flow cytometry data revealed a different story. 
While there were no significant differences between tumors at 2 hours, at 24 hours there were 
significantly higher uptake levels for tumors treated with 20k MPC DB compared to those 
treated with 20k PEG DB or 5k PEG DB (Figure 11 A, Figure 11C). Additionally, up to 90% of 
GFP-expressing tumor cells were positive for Cy5 signal in the case of 20k MPC DB treatment 
(Figure 11B). 20k PEG DB had the second highest levels of tumoral uptake at around 80% 
positive, followed by 5k PEG DB at around 40%. These results indicate that zwitterionic MPC-
based coronas improve in vivo tumor accumulation and uptake as compared to PEG-based 
coronas. The superior pharmacokinetic properties of both 20k MPC and 20k PEG DB coronas 
appear to have both increased tumor accumulation relative to traditional 5k PEG DB coronas, but 
zwitterionic coronas improved overall tumor uptake.  
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Figure 10: Polyplex Tumor Biodistribution. A and B) Overall biodistribution at 2 hours shows 
no significant differences between polyplex tumor accumulation, but increased 5k PEG DB 
accumulation in the kidneys as compared to at 24 hours. C) Polyplex biodistribution at 24 hours 
shows increased prescence of 20k MPC DB and 20k PEG DB in kidneys relative to PEG DB. No 
significant differences between these polyplexes in tumor fluorescence.  
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Figure 11: In Vivo Tumor Uptake of Polyplexes. A) 20k MPC DB polyplexes had significantly 
increased Cy5 fluorescence in tumor cells compared to 20k PEG DB and 5k PEG DB (p=0.0005 
for PEG DB diff, p=0.0526 for 20k PEG DB diff., α=0.1). B) Both 20k MPC DB and 20k PEG 
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DB had significantly increased % of positive cells compared to 5k PEG DB (α=0.1). C) Raw Cy5 
fluorescence data shows no differences between tumor uptake at 2 hours, but larger differences 
at 24 hours.  
 
Recent work in the field of zwitterionic nanocarriers has described a “switchable” surface 
charge property of zwitterionic coronas in acidic enviroments, such as that of a tumor.57 This 
theory states that if the pH of a tumor microenvironment is low enough, the zwitterionic can 
become slightly more positively charged than negatively charged, thus facilitating cellular 
uptake. This phenomenon has not been well-characterized for MPC-based polymers, but our 
tumor results suggest that further study of these properties is warranted.  
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CHAPTER IV 
CONCLUSION 
 In this work, we have synthesized and studied 6 unique siRNA polyplex corona 
chemistries building on previous work that optimized the core forming polymer block. We have 
shown that high molecular weight coronas composed of either PEG or zwitterionic MPC 
improve polyplex stability, resist protein adsorption, and significantly enhance intravenous 
polyplex pharmacokinetics over carriers containing lower molecular weight PEG and MPC. 
Additionally, we have demonstrated that polyplexes containing brush-like PEG chains 
(POEGMA) do not significantly improve pharmacokinetic properties over traditional linear PEG. 
We utilized high resolution intravital microscopy to characterize these pharmacokinetic 
parameters and to thoroughly compare zwitterionic to PEG-based coronas, a comparison that has 
not yet been made in the context of in vivo siRNA polyplex properties. Finally, we discovered 
that while there were few pharmacokinetic differences between 20k PEG and 20k MPC coronas, 
the zwitterionic coronas significantly improved in vivo luciferase silencing through superior 
tumor accumulation and tumor cell uptake properties. This work has important implications for 
optimization of siRNA nanocarriers used for systemic cancer therapeutics. Additionally, our 
findings are broadly applicable to the field of drug delivery science for optimization of 
nanomaterials to improve their efficacy in cancer-related applications.  
 
 
 
 
 29 
 
CHAPTER V 
MATERIALS and METHODS 
 
Materials 
All materials were purchased from Sigma Aldrich unless otherwise described. Inhibitors were 
removed from dimethylaminoethyl methacrylate (DMAEMA) and buty methacrylate (BMA) 
using an activated aluminum oxide column. All DNA or siRNA oligonucleotides were purchased 
from Integrated DNA Technologies (Coralville, IA, USA).  
 
Polymer Synthesis 
All polymers were synthesized using 4-cyano-4-(ethylsulfanylthiocarbonyl)sulfanylpentanoic 
acid (ECT) as an initial chain transfer agent. ECT was synthesized in house according to 
previously published methods.62 PEG DB was synthesized as previously described by coupling a 
5 kDa hydroxyl-terminated PEG (JenKem, USA) to ECT by DCC DMAP coupling. ECT was 
added to the 5 KDa PEG at a 10:1 molar ratio. Dicyclohexyl carbodiimide (DCC) and 4-
dimethylaminopyridine (DMAP) were added at 5 molar equivalents the amount of PEG. The 
coupling reaction was stirred at room temperature for 48 hours and the final product was purified 
as previously described.62 From the 5 kDa PEG macroCTA, DMAEMA and BMA were RAFT 
polymerized at 50:50 molar ratios using AIBN as an initiator (10:1 CTA:Initiator ratio) in 10% 
w/v dioxane. Reactions were planned with an aimed degree of polymerization of 240, in order to 
achieve 75-80 repeating units each of DMAEMA and BMA (at a 65-70% monomer conversion 
rate).  The reaction was nitrogen purged for 30 minutes and then was stirred at 65 ˚C for 24 
hours. The final reaction mixture was dialyzed into methanol, then water, and lyophilized. 20k 
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PEG DB was synthesized using the same methods as for the 5k PEG DB polymers, but a 20kDa 
Y-shaped hydroxyl PEG (JenKem, Plano TX,  USA) was conjugated to ECT to create the 
appropriate macroCTA. Zwitterionic MPC DB was synthesized in a two step process. First, 
DMAEMA and BMA were RAFT polymerized at the same monomer feed ratios and conversion 
estimates described above. 1H NMR was used to evaluate conversion rate. This random 
DMAEMA-BMA copolymer (DB ECT) was then used as a macroCTA to polymerize a 
homopolymer block of 2-(methacryoyloxyethyl) phosphorylcholine. For a 20,000 kDa corona or 
a 10, 000 kDa corona, target degree of polymerizations of 75 and 40 were used respectively. 
These polymerizations used AIBN at a 5:1 CTA: initiator ratio and 10% w/v anhydrous 
methanol. Reactions were purged with nitrogen for 30 minutes before heating to 65 ˚C for 24 
hours. Final reaction products were dialyzed in methanol, then water, and lyophilized. Polymers 
with POEGMA (poly(ethylene glycol) ethyl ether methacrylate) (Mn =950) in the corona were 
synthesized in a similar method, but using a 10:1 CTA:initiator ratio and dioxane as a reaction 
solvent.. Prior to polymerization, inhibitors were removed from POEGMA monomers by first 
dissoving in anhydrous THF, running through an alumna column, and then drying using a 
rotovap system. Lower monomer conversion rates of 40-50% were achieved with POEGMA 
monomers, so aimed degrees of polymerization were adjusted accordingly.  
All polymers were characterized using 1H nuclear magnetic resonance spectroscopy 
(Bruker, 400 MHz). Polymer polydispersity was evaluated with DMF mobile phase gel 
permeation chromatography (GPC, Agilent Technologies, CA). All NMR spectra are shown in 
Supplemental Figure S1.   
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Polyplex Formation and Encapsulation Efficiency 
All polyplexes in this work were first complexed with siRNA in 10 mM or 100 mM citrate 
buffer at pH4, allowed to sit for 30 minutes, and then the pH was raised to 7.4 using pH 8 
phosphate buffer at 5x the volume of the pH 4 solution. Polyplexes encapsulation efficiency at 
various N:P ratios was evaluated using a Quant -iT Ribogreen assay kit (ThermoFisher, USA). 
Assay solutions were prepared based on manufacturer’s instructions, and Ribogreen fluorescence 
was measured using the high range assay. Polyplex solutions were prepared at 100 nM siRNA, 
and 50 uL of polyplex solution was diluted by half in 1X TE buffer, followed by addition of 100 
uL Ribogreen reagent to each well. Fluorescence was measured at 520 nm and encapsulation 
efficiency was calculated by normalizing fluorescence of polyplex solutions to fluorescence of 
siRNA-only control solutions.  
 
Polyplex Stability Evaluations 
 Polyplex diameters and zeta potentials were measured using dynamic light scattering 
(Zetasizer Nano ZS, Malvern Instruments, Westborough, MA). For these measurements, 
polyplexes were prepared at final concentrations of 0.167 mg/mL. For stability measurements, 
each polyplex solution was incubated with 0.1 or 0.25 M NaCl solutions. Salt solutions made up 
20% or less of the total solution volume to avoid significant pH changes.  
Polyplex stability was also measured in FBS and heparan sulfate through a FRET assay 
described previously.33, 62, 70 Briefly, polyplexes were co-loaded with DNAs conjugated with 
either Alexa Fluor 488 or Alexa Fluor -546 dyes  , forming Forster resonance energy transfer 
pairs.  Intensity of fluorescence emission after excitation at 488 nm was measured at 514 and 572 
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nm, evaluated using a fluorescence plate reader (Tean Infinite F500, Mannedorf, Switzerland). % 
FRET for each polyplex sample was calculated as:  
 
𝐼572
𝐼572 + 𝐼514
 
For FBS-based FRET challenge, polyplexes were incubated at concentrations of 100 nM siRNA 
per well with 10, 20, 40, 40, or 50% FBS. FRET signal of polyplexes incubated with FBS was 
compared to that of polyplexes in PBS alone. In all cases, black, clear bottom 96 well plates were 
used for fluorescence measurements. FRET signal was tracked over the course of 100 minutes at 
5 minute intervals.  
 Polyplex stability was also evaluate in response to heparin salts. Again, polyplexes were 
prepared to have final concentrations of 100 nM siRNA per well. In each well, 90 uL of 
polyplexes were incubated with 10 uL of various concentrations of heparin salts, ranging from 2 
U/mL to 100 U/mL final per well concentrations. FRET signal was then evaluated similarly to 
the above FBS-based method.  
 
Hemolysis Assay 
 Red blood cell hemolysis assay was performed using methods described previously.65 
Blood was drawn from consenting human donors according to an IRB-approved protocol. In 
short, red blood cells (RBCs) were isolated from whole blood and diluted into buffer solutions of 
pH 5.6, 6.2, 6.8, and 7.4. Polyplexes were prepared at 1, 5 and 40 ug/mL polymer and were 
incubated with red blood cells at the various pH values for 1 hour in round-bottom 96 well 
plates. Negative controls and positive controls of red blood cells in buffer only or Triton-X, 
respectively, were also used for analysis. The RBCs were then centrifuged and supernatants were 
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analyzed for absorbance at 450 nm using a plate reader. Percent hemolysis was evaluated by 
subtracting background buffer-only RBC absorbance and normalizing to Triton-X controls.  
 
Production of stable luciferase-expressing MDA-MB-231 breast cancer cells and luciferase-
expressing NIH 3T3 Mouse fibroblast cells 
 Lentivirus was produced by transfecting HEK-293T cells with pGreenFire1-CMV 
plasmid, along with pMDLg/pRRE, pRSV-Rev, and pMD2.G packaging plasmids with 
Lipofectamine 2000 as a transfection reagent. Media supernatant containing lentivirus was then 
collected at 48 and 72 hours. For transfection of MDA-MB-231 and NIH-3T3 cell lines, 
lentiviral media was added to the cells containing 6 ug/mL poybrene for 24 hours of incubation. 
Cells were analyzed post-transduction by detection of GFP using flow cytometry (BD LSR II 
Flow Cytometer, San Jose, CA, USA). Cells were selected for vector expression by growing in 
puromycin-containing media.  
 
Cell Culture 
All cells used for this manuscript were cultured in Dulbecco’s modified Egle’s medium (DMEM, 
Gibco Cell Culture, Carlsbad, CA), containing 4.5 g/L glucose, 10 % fetal bovine serum (Gibco), 
and 0.1% gentamicin (Gibco).  
 
Cell Viability 
 Luciferase-expressing NIH 3T3 cells were seeded in a 96-well plate at 20,000 cells/mL 
(2000 cells per well). After 24 hours, polyplex solutions were introduced to the wells using an 
N:P ratio of 20 along with 100 nM scrambled siRNA per well. After 24 hours, polyplex-
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containing media was removed from the cells and replaced with media containing luciferin 
substrate (150 ug/mL). After incubating for 5 minutes, cells were imaged using an IVIS Lumina 
III imaging system (Caliper Life Sciences, Hopkinton, Massachusetts). Luciferin-containing 
media was then replaced with normal media for 24 more hours, followed by another round of 
IVIS imaging with luciferin media at 48 hours. Luminescence signal was compared to untreated 
controls for analysis.  
In vitro luciferase silencing of MDA-MB 231 cells 
 Luciferase-expressing MDA-MB 231 cells were seeded in 96 well plates at 2000 cells per 
well and allowed to grow for 24 hours. Polyplex solutions containing either luciferase siRNA or 
scrambled siRNA at 100 nM were then incubated with MDA-MB 231 cells in quadruplicate. 
After 24 hours, media was replaced with luciferin-containing media (150 ug/mL) and 
luminescence was evaluated by IVIS imaging. Luciferin-containing media was then replaced 
with normal media until 48 hours, at which point luciferin media was reintroduced, and 
luminescence again evaluated. For analysis of knockdown, all data were normalized to 
scrambled control polyplexes to account for any toxicity effects.  
Uptake by MDA-MB 231 cells 
 Non-luciferase expressing MDA-MB-231 cells were seeded in 12-well plates at 80,000 
cells per well. Polyplexes were formed containing 100 nM of Alexa Fluor 488-conjugated DNA 
in complete media. After 24 hours, polyplex-containing media was removed. Cells were washed 
with PBS, trypsinized for 10 minutes in 0.25% trypsin, and centrifuged at 450 xg for 7 min. Cell 
pellets were then resuspended in PBS containing 0.04% trypan blue (to quench extracellular 
fluorescence) just prior to adding them to a flow cytometer (FACSCalibur, BD Biosciences, 
Franklin Lakes, MJ, USA). Cells were monitored for AlexaFluor 488 fluorescence at excitation 
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and emission wavelengths of 488 and 519 nmn, respectively. Quantification of % uptake was 
performed using FlowJo software (FlowJo, LLC, Ashland, OR). Untreated MDA-MB 231 cells 
were used as negative controls.  
Isothermal Titration Calorimetry 
 Isothermal Titration Calorimetry experiments were performed using a MicroCal VP-ITC 
(Malvern, USA) in the Vanderbilt Center for Structural Biology Core. Polyplexes were prepared 
at concentrations of 0.5 mg/mL polymer as described above. Bovine Serum Albumin (BSA) was 
dissolved from lyophilized powder at 15 mg/mL in buffer solutions exactly matching the 
composition of polyplex buffer. Titration experiments were carried out at 37 ⁰C using a reference 
power of 10 ucal/ sec, 300 second initial delay, 307 rpm stirring speed. Each injection was 10 
uL, with a duration of 20 sec, spacing of 260 seconds, and filter period of 2 seconds. A control 
consisting of heat of dilution of BSA into buffer only was subtracted from titration data. All data 
analysis was performed in Origin, using a one set of sites binding model to determine 
thermodynamic parameters. A cationic control polymer consisting of DMAEMA only in the 
corona, as previously described33, was used as a positive control for protein adsorption.  
Complement Assay 
 All materials for the hemolysis-based complement assay were purchased from 
Complement Technologies (Tyler, TX, USA). siRNA polyplexes were prepared at 50 nM 
siRNA. Complement sera was prepared at five dilutions (1:20, 1:40, 1:80, 1:160, 1:320), and was 
then Antibody-sensitized sheep red blood cells were prepared at 2x 108 cells/mL in GVB ++ 
buffer. In each test tube, 10 0uL of complement sera was added to 100 uL pof polyplexes and 
incubated for 30 minutes. Then 100 uL of antibody-sensitized RBCs were added to each tube and 
the mixtures were incubated at 37 ⁰C for 1 hour with intermittent shaking. All samples were then 
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centrifuged and supernatants were transferred to a 96 well plate. Absorbance at 541 nm was then 
measured on a plate reader. Absorbance values were used to determine transmittance and 
absorption (1-transmittance). Percent lysis was calculated by subtracting absorption of PBS/RBC 
only controls from sample absorption and dividing by absorption for complete lysis controls 
(water+RBCs) minus absorption of PBS/RBC controls. Percent lysis at each complement 
dilution was plotted and compared to control samples containing complement proteins only (no 
polyplexes).  
Polyplex pharmacokinetics, biodistribution, and intravital microscopy 
In vivo polyplex preparation 
 For in vivo polyplex preparations, polymers were complexed with 1 mg/kg Cy5-
conjugated DNA olignonucleotides in 100 mM pH4 citrate buffer. Complexing solutions were 
then loaded into 20 kDa MWCO dialysis tubing (Spectrum Laboratories, Rancho Dominguez, 
CA) and dialyzed into PBS -/- overnight. Polyplex formation was confirmed by dynamic light 
scattering (described above) immediately prior to in vivo injections.  
Intravital microscopy 
 Male CD-1 mice (Charles River) (n=4 per group), were anesthetized using isoflurane and 
immobilized on heated confocal microscope stage. Prior to imaging, mouse ears were naired. 
Microscope immersion fluid was used to immobilize the mouse ear on a glass coverslip. 
Intravital microscopy was performed using a Nikon Czsi+ system with a Nikon Eclipse Ti-oE 
inverted microscopy base, Plan ApoVC 20x differential interference contrast N2 objective, 0.75 
NA, Galvano scanner, and 543 dichroic mirror. All image analysis and acquisition was done 
using Nikon NIS-Elements AR version 4.30.01. A laser power of 98 was used throughout. Ear 
veins were detected using the light microscope and images were focused to the plane of greatest 
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vessel width, where flowing red blood cells were clearly visible.  Once the ear was in focus, 
microscope was switched to confocal laser mode and set to image continuously every second. 
The mouse was then injected with 100 uL polyplex solution via tail vein at a 1 mg/kg dose, and 
Cy5 fluorescence in ear veins was monitored for 20 minutes. For image analysis, initial 
background fluorescence was subtracted, and circular regions of interest were highlighted within 
the mouse ear vessels. Fluorescence from these regions of interest was quantified and 
background fluorescence was subtracted. Intensity values were normalized to initial peak 
intensity. Fluorescence decay curves were modeled as one-compartment systems using single 
phase exponential decay. Pharmacokinetic parameters were calculated using Graphpad Prism 
analysis software.  
 
Biodistribution 
 After 20 min of monitoring via intravital microscopy, animals were sacrificed. Organs 
were removed and immediately imaged for Cy5 fluorescence using an IVIS system. 
Fluorescence was quantified using an IVIS Lumina Imaging system (Xenogen Corporation, 
Alameda, CA, USA) at excitation and emission wavelengths of 620 and 670 nm, respectively.  
 
In Vivo Tumor Gene Silencing 
 Athymic female nude mice (4-6 weeks old, Jackson Laboratory) were injected in the 
mammary fatpad on each side with 1 x 106 Luciferase expressing MDA-MB-231 cells in a 50:50 
mixture of Matrigel:DMEM (serum-free). Tumor growth was followed until they reached 
approximately 75 mm3. Polyplexes were prepared bearing either luciferase or scrambled siRNA 
at 1 mg/kg as described for pharmacokinetic studies. Animals were injected i.p. with luciferin 
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substrate (150mg/kg) imaged for baseline tumor luminescence using an IVIS system, and then 
were subsequently injected with polyplexes via tail vein. Mice were re-injected with luciferin 
substrate on Days 1, 3, 5, 7, and 10 post-treatment. Luminescence signal of each individual 
tumor was compared to its baseline pre-treatment signal, and each relative luminescence value 
was normalized to the average relative luminescence of respective scrambled siRNA polyplex 
groups (n=6-10 tumors per group). Body weight measurements of all mice were recorded every 
day of the study period to note any signs of toxicity.  
 
Biodistribution of Tumor Bearing Mice 
 Biodistribution studies for athymic female nude tumor-bearing mice (Jackson 
Laboratory) were conducted using the same methods as biodistribution studies for the male CD-1 
mice. All polyplexes were similarly loaded with Cy5 conjugated DNA and fluorescence was 
measured in heart, lungs, kidneys, liver, spleen, and tumors. Organs were excised at 2 hour and 
24-hour time points post tail vein injection. 
 
In Vivo Polyplex Uptake by MDA-MB-231 breast tumors 
 Tumors isolated from mice during above-described biodistribution experiments were then 
used for flow cytometry studies of polyplex uptake. Tumors were cut into small pieces, washed 
with HBSS containing Ca and Mg, and then processed using an enzyme mix containing 
collagenase (0.5 mg/mL, Roche Life Sciences, Indianapolis, IN, USA) and DNAse (0.19 mg/mL, 
BioRAD, Hercules, CA, USA) in DMEM. After 1 hour incubation in enzyme mix, the tumors 
were centrifuged and re-suspended in HBSS without Ca and Mg, and then incubated with 5 mM 
EDTA for 20 minutes. Tumors were then centrifuged and the pellets were re-suspended in HBSS 
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with Ca and Mg and filtered using a 70 um Nylon cell strainer. Filtrate was then washed once 
more with HBSS containing Ca and MG, and then incubated in ACK lysis buffer (Thermo Fisher 
Scientific, USA) for 2 minutes before being diluted in 20 mL of PBS -/-. Cells were then pelleted 
and re-suspended in 1-2 mL PBS-/- prior to running on a flow cytometer (BD LSRii, BD 
Biosciences, San Jose, CA, USA). Uptake analysis was performed in FlowJo.  
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Supplemental Figure S1: NMR of all polymers synthesized in this work. Conjugation 
efficiency for 5k PEG ECT and 20k PEG ECT were 86% and 95 %, respectively. Monomer 
conversion rate for DB ECT random copolymer was 65%. All NMRs were performed in 
deuterated chloroform except for 10k MPC DB and 20k MPC DB, which were in MeOD.  
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Supplemental Figure S2: Raw average radiance data for polyplexes 20 minutes post-injection. 
Overall radiance for 5k PEG DB was already diminished in most organs by 20 minutes 
compared to other polyplexes.  
